A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care

Thermal Burns Clinical Trial

Official title:

A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02278718
• Other study ID #: MW2012-01-01
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: May 2015
• Est. completion date: December 2022

Study information

• Verified date: July 2022
• Source: MediWound Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be a two-arms study intending to demonstrate superiority of NexoBrid treatment over SOC in children with thermal burns. The study objective is to evaluate the safety and clinical benefit of NexoBrid in hospitalized children (0-17 years) with deep partial and/or full thickness thermal burns of 1-30% TBSA and to compare NexoBrid to standard of care (SOC).

Description:

A total of 160 patients will be randomized into NexoBrid and SOC treatment (80 patients per arm).

Age distribution will be managed as follows:

• 45 patients 0-23 months old

• 45 patients 24 months-3 years old

• 30 patients 4-11 years old

• 20 patients 12-17 years old The remaining 20 patients will be enrolled to any of the above groups, per their age during enrollment.

The study will be conducted in three stages. In Stage I, at least 24 children age 4-18 years, hospitalized in burn units, with deep partial thickness burns ranging from 1%-30% TBSA, and who meet the entrance criteria, will be enrolled. Upon completion of stage I, a safety analysis will be performed on safety parameters and the results will be evaluated by a Data Safety Monitoring Board (DSMB) as defined in the agreed charter. If the DSMB does not have any safety concerns, Stage II will commence, this time enrolling at least 26 additional children aged of 1-18 years according to the study procedures. A DSMB will be convened to assess the safety data of the first 50 patients enrolled at stages 1 & 2. If the DSMB has not found any safety concerns, stage III will commence in which patients from the age of birth to 18 years will be included (stage III will include 110 remaining patients required to reach a total of 160 patients).

Following the enrollment of a subject to the study and prior to randomization, physicians will define one or more Target Wounds (TWs) per subject according to TWs definition. All subjects' DPT and FT burns that fit the specified criteria are intended to receive study treatment per randomized study arm and therefore, must be designated as TWs.

Prior to eschar removal treatment with NexoBrid or SOC subjects will be medicated with appropriate analgesia and undergo wound cleansing and dressing of all wounds with antibacterial solutions. Following wound cleansing and antibacterial treatments, subjects will undergo the eschar removal process as per treatment assignment (NexoBrid or SOC, following randomization). Subsequent to eschar removal, all wounds will be assessed and treated in the same manner, in accordance with post-eschar removal wound care strategy. Furthermore, subjects will undergo daily assessments (Vital signs (VS) and pain assessments) for one week and weekly assessments thereafter, until wound closure. Following wound closure, subjects will be followed up at 6 weeks, 12 weeks, and after that, at 6, 12, 18 and 24 months (for a blinded assessment of cosmesis, function and QoL evaluation).

All subjects will be invited to one additional extended follow up visit that will occur at least 30 months after wound closure confirmation for a blinded assessment of cosmesis, function and QoL evaluation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 145
• Est. completion date: December 2022
• Est. primary completion date: April 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 17 Years

Eligibility

Inclusion Criteria

1. Stage 1: Males and females between 4 years to 18 years of age, Stage 2 (upon DSMB review): Males and females between 1 year to 18 years of age, Stage 3 (upon DSMB review): Males and females between 0 years to 18 years of age.

2. Thermal burns caused by fire/flame, scalds or contact.

3. Patient total burns area = 1% DPT and / or FT,

4. Patient total burns area should be = 30% TBSA; SPT, DPT and/or FT in depth,

5. Signed written informed consent by a legal guardian can be obtained within 84 hours of the burn injury.

At least one wound (a continuous burn area which can be treated in one session; might include several anatomical areas) in a patient should meet all following criteria:

1. Wound that is = 1% TBSA (DPT and/or FT) (not including face, perineal or genital),

2. Wound is composed of DPT and/or FT in depth. Superficial partial thickness areas may be included in the wound area only if cannot be separated from deeper areas (e.g. surrounded by or mixed with DPT areas) and might interfere with the treatment of the deeper areas,

3. Wound that is potentially intended for surgical eschar removal,

4. Wound's blisters can be unroofed, as judged by the investigator.

Exclusion Criteria:

1. Patients weighing less than 3kg,

2. Patients who are unable to follow study procedures and follow up period,

3. Patients with electrical or chemical burns,

4. Patient with a continuous burn area above 15% TBSA,

5. Patients with no DPT and/or FT burn area (only SPT wounds),

6. Patient with circumferential anterior/posterior trunk fire/flame burns, >15% TBSA (Circumferential is defined as encircling = 80% of the trunk circumference),

7. The following pre-enrolment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),

8. Patients with diagnosed infections,

9. Diagnosis of smoke inhalation injury,

10. Patients with pre-enrolment wounds which are covered by eschar saturated with iodine or by SSD pseudoeschar (e.g. pseudoeschar as a result of >12h SSD treatment),

11. Patients with pre-enrolment escharotomy,

12. Pregnant women (positive pregnancy test) or nursing mothers,

13. Poorly controlled diabetes mellitus (HbA1c>9%),

14. Known Cardio-pulmonary disease, oxygen-dependent pulmonary diseases, broncho-pneumonia, uncontrolled asthma,

15. Known conditions which interfere with circulation (peripheral vascular disease, edema, lymphedema, surgery to the regional lymph nodes, obesity),

16. Any known conditions that would preclude safe participation in the study or adding further risk to the basic acute burn trauma (such as immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, pulmono-cardiovascular, liver or neoplastic disease),

17. ASA greater than 2

18. Chronic systemic steroid intake,

19. History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or papain,

20. Current (within 12 months prior to screening) suicide attempt,

21. Enrollment in any investigational drug trial within 4 weeks prior to screening,

22. Current (within 12 months prior to screening) alcohol (daily consumption > 3 units for males and >2 units for females) or drug abuse,

23. Prisoners and incarcerated

24. Patients who might depend on the clinical study site or investigator.

25. Patient expresses objection to participate in the study.

26. Patients with other severe cutaneous trauma at the same sites as the burns (i.e. blunt, avulsion or deep abrasion) or previous burn(s) at the same treatment site(s)

27. General condition of patient would contraindicate surgery

Related Conditions & MeSH terms

• Burns
• Thermal Burns

Intervention

Drug:
• NexoBrid
NexoBrid is an enzymatic debriding agent for Eschar Removal.

Procedure:
• Standard of Care
Surgical or Non-Surgical methods for Eschar Removal

Locations

Country	Name	City	State
Belgium	University Hospital, Department of Plastic Surgery	Gent
Georgia	S. Khechinashvili University Hospital	Tbilisi
Germany	Unfallkrankenhaus Berlin Zentrum für Schwerbrandverletzte mit Plastischer Chirurgie	Berlin
Germany	Klinikum Stuttgart - Olgahospital	Stuttgart
Hungary	MRE Bethesda Gyermekkórháza	Budapest
Hungary	B.A.Z Megyei Kórház és Egyetemi Oktatókórház	Miskolc
Hungary	Klinikai Kozpont Gyermekgyogyaszati Klinika	Pécs
India	Krishna Rajendra Hospital	Mysuru
India	Dr. Ram Manohar Lohia Hospital, Baba Kharak Singh Marg	New Delhi	Delhi
India	Vardhman Mahavir Medical College (VLCC) and Safdarjung Hospital	New Delhi
Italy	Universitary Integrated Hospital Verona (AOUI Verona),	Verona
Netherlands	Acute Burn Care &Trauma Surgery, Dept Surgery/Burn Center, Rode Kruis Ziekenhuis, LUMC University Leiden	Beverwijk
Poland	Uniwersytecki Szpital Dzieciecy w Krakowie	Kraków
Poland	Szpital Dzieciecy im.prof.dr.med Jana Bogdanowicza, Oddzial Chirurgii i Urologii Dzieciecej z Pododdzialem Leczenia Oparzen	Warszawa
Romania	Spitalul Clinic de Urgenta pentru Copii "Sfanta Maria"	Iasi
Romania	Spitalul Clinic de Urgenta Tg- Mures	Târgu-Mures
Slovakia	Univerzitná nemocnica Bratislava, Klinika popálenin a rekonštrukcnej chirurgie	Bratislava
Spain	La Paz University Hospital	Madrid
Spain	Boulevar Sur s/n	Valencia
Ukraine	CNPE "City clinical hospital of immediate and urgent medical aid n.a.Meshchaninov" of Kharkiv CC and State institution 'Zaitsev V.T. Institute of general and urgent surgery of the National academy of medical sciences of Ukraine'	Kharkiv
Ukraine	Communal institution "Odessa Regional Clinical Medical Center"	Odesa
United Kingdom	Birmingham Children´s Hospital NHS Foundation Trust	Birmingham
United Kingdom	Royal Manchester Children's Hospital	Manchester
United States	Shriners Hospital for Children	Boston	Massachusetts
United States	Shawn Jekins Children's Hospital	Charleston	South Carolina
United States	University Of Florida	Gainesville	Florida
United States	University of Iowa Hospitals and Clinics	Iowa City	Iowa
United States	University of Kansas Medical Center Research Institute, Inc.	Kansas City	Kansas
United States	University of Miami	Miami	Florida
United States	Drexel University	Philadelphia	Pennsylvania
United States	Maricopa Special Health Care District	Phoenix	Arizona
United States	Legacy Emanuel Hospital & Health Center dba Legacy Research Institute	Portland	Oregon
United States	University of Utah	Salt Lake City	Utah
United States	Harborview Medical Center	Seattle	Washington
United States	Stony Brook University Medical Center	Stony Brook	New York
United States	The University of South Florida Board of Trustees	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
MediWound Ltd

Countries where clinical trial is conducted

United States,  Belgium,  Georgia,  Germany,  Hungary,  India,  Italy,  Netherlands,  Poland,  Romania,  Slovakia,  Spain,  Ukraine,  United Kingdom, 

References & Publications (1)

Rosenberg L, Krieger Y, Bogdanov-Berezovski A, Silberstein E, Shoham Y, Singer AJ. A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT. Burns. 2014 May;40(3):466-74. doi: 10.1016/j.burns.2013.08.013. Epub 2013 Sep 26. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Earlier eschar removal (in days)	Demonstrate superiority over SOC for eschar removal as measured by a survival analysis of incidence of complete eschar removal as a function of time. Eschar removal will be measured at the end of the debridement starting from randomization date.	participants will be followed from randomization date and daily for the duration of hospital stay, an expected average of 3 weeks

External Links

•   Related Info